Last Updated: October 26, 2026

Details for New Drug Application (NDA): 217171

✉ Email this page to a colleague

NDA 217171 describes SYFOVRE, which is a drug marketed by Apellis Pharms and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug. Additional details are available on the SYFOVRE profile page.

The generic ingredient in SYFOVRE is pegcetacoplan. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the pegcetacoplan profile page.

Summary for 217171

Tradename:	SYFOVRE
Applicant:	Apellis Pharms
Ingredient:	pegcetacoplan
Patents:	13

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 217171

Generic Entry Date for 217171^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: 10,035,822 Dosage: SOLUTION;INTRAVITREAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 217171

Mechanism of Action	Complement Inhibitors

Suppliers and Packaging for NDA: 217171

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171	NDA	Apellis Pharmaceuticals, Inc.	73606-020	73606-020-01	1 VIAL, GLASS in 1 CARTON (73606-020-01) / 3 mL in 1 VIAL, GLASS
SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171	NDA	Apellis Pharmaceuticals, Inc.	73606-020	73606-020-02	1 VIAL, GLASS in 1 CARTON (73606-020-02) / 3 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVITREAL			Strength	15MG/0.1ML (15MG/0.1ML)
Approval Date:	Feb 17, 2023	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	May 14, 2026
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:	Feb 22, 2026
Regulatory Exclusivity Use:	NEW PRODUCT
Patent:	10,035,822	Patent Expiration:	Nov 15, 2033	Product Flag?		Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 217171

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apellis Pharms	SYFOVRE	pegcetacoplan	SOLUTION;INTRAVITREAL	217171-001	Feb 17, 2023	9,056,076	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.